Inozyme Pharma Inc

More Details of Inozyme Pharma Inc Company

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The Company is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The Company also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).

Company Info

Company codeINZY

Company nameInozyme Pharma Inc

IPO dateJul 24, 2020

Founded at2015

CEODr. Douglas A. (Doug) Treco, Ph.D.

Number of employees67

Security typeOrdinary Share

Fiscal year-endJul 24

Address321 Summer Street

CityBOSTON

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02210

Phone18573304340

Websitehttps://www.inozyme.com/

Company codeINZY

IPO dateJul 24, 2020

Founded at2015

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Axel Bolte

Director

266.70K

--

Dr. Matthew Winton, Ph.D.

Chief Operations Officer

7.39K

--

Dr. Robert (Rob) Hopfner, Ph.D.

Independent Director

--

Dr. Martin William Edwards, M.D.

Independent Director

--

Mr. Edward T. Mathers

Independent Director

--

Dr. Sarah M. Bhagat, Ph.D.

Independent Director

--

Mr. Reinaldo M. Diaz

Lead Independent Director

--

Dr. Douglas A. (Doug) Treco, Ph.D.

Chairman of the Board, Chief Executive Officer

--

Ms. Lynne Sullivan, CPA

Independent Director

--

Mr. Erik Harris

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Axel Bolte

Director

266.70K

--

Dr. Matthew Winton, Ph.D.

Chief Operations Officer

7.39K

--

Dr. Robert (Rob) Hopfner, Ph.D.

Independent Director

--

Dr. Martin William Edwards, M.D.

Independent Director

--

Mr. Edward T. Mathers

Independent Director

--

Dr. Sarah M. Bhagat, Ph.D.

Independent Director

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholder

Update time: Fri, May 16

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

Longitude Capital Management Co., LLC

9.05%

Adage Capital Management, L.P.

7.99%

Pivotal Bioventure Partners Investment Advisor LLC

6.96%

Sofinnova Investments, Inc

6.63%

Affinity Asset Advisors LLC

5.99%

Other

63.38%

Shareholder Statistics

Shareholder

Proportion

Longitude Capital Management Co., LLC

9.05%

Adage Capital Management, L.P.

7.99%

Pivotal Bioventure Partners Investment Advisor LLC

6.96%

Sofinnova Investments, Inc

6.63%

Affinity Asset Advisors LLC

5.99%

Other

63.38%

Type

Shareholder

Proportion

Hedge Fund

30.25%

Venture Capital

29.01%

Investment Advisor/Hedge Fund

12.31%

Investment Advisor

11.71%

Research Firm

0.92%

Corporation

0.69%

Private Equity

0.68%

Individual Investor

0.54%

Bank and Trust

0.10%

Other

13.80%

Institutional Shareholding

Update time: Tue, Mar 4

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

216

60.54M

94.21%

-7.78M

2024Q4

214

60.27M

93.82%

-9.91M

2024Q3

191

62.40M

99.19%

-7.69M

2024Q2

189

61.61M

98.84%

-3.38M

2024Q1

182

57.68M

93.47%

-8.16M

2023Q4

168

57.62M

93.40%

-5.18M

2023Q3

173

55.08M

89.40%

+6.47M

2023Q2

167

38.83M

84.32%

-10.19M

2023Q1

159

36.61M

84.56%

-4.82M

2022Q4

151

33.67M

83.45%

-6.75M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Longitude Capital Management Co., LLC

5.84M

9.09%

--

Apr 22, 2024

Adage Capital Management, L.P.

5.16M

8.03%

-513.63K

-9.05%

Dec 31, 2024

Pivotal Bioventure Partners Investment Advisor LLC

4.49M

7%

--

Dec 31, 2024

Sofinnova Investments, Inc

4.28M

6.66%

--

Dec 31, 2024

Affinity Asset Advisors LLC

3.97M

6.18%

+1.15M

+40.75%

Dec 31, 2024

Rock Springs Capital Management LP

3.86M

6.01%

+59.10K

+1.55%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

3.49M

5.43%

+313.70K

+9.87%

Dec 31, 2024

The Vanguard Group, Inc.

2.63M

4.1%

+8.91K

+0.34%

Dec 31, 2024

New Enterprise Associates (NEA)

2.44M

3.79%

--

Dec 31, 2024

Samsara BioCapital, LLC

1.56M

2.43%

--

Dec 31, 2024

Related ETFs

Update time: Tue, May 6

Name

Proportion

Invesco Nasdaq Biotechnology ETF

0.01%

ProShares Ultra Nasdaq Biotechnology

0.01%

iShares Micro-Cap ETF

0.01%

iShares Russell 3000 ETF

0%

iShares Russell 2000 ETF

0%

Dimensional US Core Equity 1 ETF

0%

Fidelity Nasdaq Composite Index ETF

0%

Global X Russell 2000 ETF

0%

Global X Russell 2000 Covered Call ETF

0%

DFA Dimensional US Core Equity Market ETF

0%

Invesco Nasdaq Biotechnology ETF

Proportion0.01%

ProShares Ultra Nasdaq Biotechnology

Proportion0.01%

iShares Micro-Cap ETF

Proportion0.01%

iShares Russell 3000 ETF

Proportion0%

iShares Russell 2000 ETF

Proportion0%

Dimensional US Core Equity 1 ETF

Proportion0%

Fidelity Nasdaq Composite Index ETF

Proportion0%

Global X Russell 2000 ETF

Proportion0%

Global X Russell 2000 Covered Call ETF

Proportion0%

DFA Dimensional US Core Equity Market ETF

Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

3.950USD